Oftalmol Zh.2009;3:20-23.

http://doi.org/10.31288/oftalmolzh200932023

COMPARISON OF THE EFFICACY OF DIODE LASER CYCLOPHOTOCOAGULATION, ALONE OR IN CONJUNCTION WITH AVASTIN IN THE TREATMENT OF NEOVASCULAR GLAUCOMA

Ahmed M. Emarah, MD, Mostafa A El-Helw, MD, Mohammed A Hassaballa MD, Heba A ElGuindy, MD, Mohammed A Fakery, MD

Purpose: To assess the efficacy of Avastin as an adjunct to Diode Laser cyclophotocoagulation in the treatment of Neovascular Glaucoma.
Design: Prospective, comparative interventional case series.
Method: The patients were randomly assigned into two groups: Group A was treated with Diode laser cy-clophotocoagulation alone (30 laser shots over 270 degrees of the circumference of the limbus). For our study we used the Iris Diode laser machine, the G-probe and we adjusted the settings for 2500 millisecond duration and the 3000 milli-joule and reduced the power progressively until just below the energy level that produced a pop, whereas group B received intravitreal Avastin (One milligram = 0.04 mL of 25 mg/mL) in conjunction with the Diode Laser. The preoperative Data included Etiology, mean age; follow up period, and a full ophthalmological examination with emphasis on mean IOP, iris neovascularization, pain and corneal edema.
Results: There was a significant IOP reduction in both groups p < 0,05, also there was significant reduction of pain in both groups with p = 0.023 and 0,004 respectively, group B showed significant reduction in iris neovascularization p = 0.001. There were no notable complications in our sample of patients.
Conclusion: Avastin is a useful adjunct in the treatment of Neovascular Glaucoma, the use of which should be further evaluated.
Key words: Neovascular glaucoma, diode laser, cyclophotocoagulation, intravitreal Avastin.
 

References

1.Sivack-Callcott J. A., O'Day D. M., Gass D. M. et al. Evidence based recommendations for the diagnosis and treatment of neovascular glaucoma // Ophthalmology. — 2001. — Vol. 108. — P. 1767-1776.

CrossRef 

2.Glaucomas associated with disorders of the retina, vitreous and choroids. In: Allingham R. A., Damji K. F., Freedman S. et al., ads. Shields' Textbook of Glaucoma. 5th ed. Philadelphia: Lippincott, Williams & Wilkins, 2005. — P. 328346.

3.Ng WME, Anthony A. P. Targeting angiogenesis, the un-derlying disorder in neovascular age-related macular de-generation // Can. J. Ophthalmol. — 2005. — Vol. 40. — P. 352-368.

CrossRef  

4.Tripathi R. C., Li J., Tripathi B. J. et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma // Ophthalmology. — 2001. — Vol. 105. — P. 232-237.

CrossRef  

5.Hurwitz H., Fehrenbacher L., Novotny W. et al. Bevacizumab plus iricotecan, fluorouracil, and leucovorin for metastatic colorectal cancer // N. Engl. J. Med. — 2004. — Vol. 350. — P. 2335-2342.

CrossRef   PubMed 

6.Rosenfeld P. J., Fung A. E., Puliafito C. A. Optical coher-ence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion // Ophthalmic Surg Lasers Imaging. — 2005. — Vol. 36. — P. 336-339.

CrossRef 

7.Rosenfeld P. J., Moshfeghi A. A., Puliafito C. A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration // Ophthalmic Surg Lasers Imaging. — 2005. — Vol. 36. — P. 331-335.

CrossRef

8.Avery R. L., Pieramici D. J., Rabena M. D. et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration // Ophthalmology. — 2006. — Vol. 113. — P. 363-372.

CrossRef  PubMed

9.Kahook M. Y., Schuman J. S., Noecker R. J. Intravitreal bevacizumab in a patient with neovascular glaucoma // Ophthalmic. Surg. Lasers Imaging. — 2006. — Vol. 37. — P. 144-146.

CrossRef  

10.Davidorf F. H., Mouser J. G., Derick R. J. Rapid improve-ment of rebuosis iridis from a single bevacizumab (Avastin) injection // Retina. — 2006. — Vol. 26. — P. 354-356.

CrossRef  PubMed

11.Shahin Y., Kamran H., Mohammad P. Intravitreal Bevaci-zumab (Avastin) Injection for Neovascular Glaucoma // J. Claucoma. — 2007. — Vol. 16. — P. 437-439.

CrossRef  PubMed

12.van Wjngaarden P., Coster D. J., Williams K. A. Inhibitors of ocular neovascularization: promises and potential problems // JAMA. — 2005. — Vol. 293. — P. 1509-1513.

CrossRef  PubMed

13.Chilov M. N., Grigg J. R., Playfair T. J. Bevacizumab (Avastin) for the treatment of neovascular glaucoma // Clin. Exp. Opthalm. — 2007 Jul. — Vol. 35 (5). — P. 494496.

CrossRef  PubMed

14.Carmeliet P., Tessier-Lavigne M. Common mechanisms of nerve and blood vessel wiring // Nature. — 2005. — Vol. 436. — P. 193-200.

CrossRef  PubMed  

15.Genentech Inc. Avastin (Bevacizumab) for Intravenous Use. Full Prescribing Information. Accissed 9 Aug 2006. 

16.Spaide R. F., Laud K., Fine H. F. et al. Intravitreal beva-cizumab treatment of choroidal neovascularization secondary to age-related macular degeneration // Retina. — 2006. — Vol. 26. — P. 383-390.

CrossRef   PubMed